JP2020517632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517632A5 JP2020517632A5 JP2019556836A JP2019556836A JP2020517632A5 JP 2020517632 A5 JP2020517632 A5 JP 2020517632A5 JP 2019556836 A JP2019556836 A JP 2019556836A JP 2019556836 A JP2019556836 A JP 2019556836A JP 2020517632 A5 JP2020517632 A5 JP 2020517632A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- oligonucleotide
- population
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 64
- 108091034117 Oligonucleotide Proteins 0.000 claims description 52
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 22
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 150000004713 phosphodiesters Chemical group 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000011319 anticancer therapy Methods 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487292P | 2017-04-19 | 2017-04-19 | |
| US62/487,292 | 2017-04-19 | ||
| PCT/US2018/028259 WO2018195249A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for stat3 inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517632A JP2020517632A (ja) | 2020-06-18 |
| JP2020517632A5 true JP2020517632A5 (enExample) | 2021-05-20 |
| JP7237009B2 JP7237009B2 (ja) | 2023-03-10 |
Family
ID=63856906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556836A Active JP7237009B2 (ja) | 2017-04-19 | 2018-04-19 | Ｓｔａｔ３阻害のためのｐ－エトキシ核酸 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11041153B2 (enExample) |
| EP (1) | EP3612159A4 (enExample) |
| JP (1) | JP7237009B2 (enExample) |
| KR (1) | KR102775941B1 (enExample) |
| CN (1) | CN110636836B (enExample) |
| AU (1) | AU2018255352B2 (enExample) |
| BR (1) | BR112019021771A2 (enExample) |
| CA (1) | CA3058018A1 (enExample) |
| EA (1) | EA201992485A1 (enExample) |
| IL (1) | IL269608B2 (enExample) |
| SA (1) | SA519410315B1 (enExample) |
| SG (1) | SG11201909336VA (enExample) |
| WO (1) | WO2018195249A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102755601B1 (ko) | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
| US10927379B2 (en) | 2016-09-16 | 2021-02-23 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| US12234457B2 (en) | 2017-04-19 | 2025-02-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for BCL2 inhibition |
| CN113238053B (zh) * | 2021-04-30 | 2022-05-13 | 四川大学华西医院 | 一种用于检测stat3二聚化的质粒 |
| CN116082496B (zh) * | 2022-08-26 | 2025-05-27 | 华中师范大学 | 靶向STAT3蛋白Ser701磷酸化的抗原肽、抗体及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248671A (en) | 1989-02-15 | 1993-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5602240A (en) * | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US6111094A (en) | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| AU683957B2 (en) | 1993-11-05 | 1997-11-27 | Amgen, Inc. | Liposome preparation and material encapsulation method |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US7309692B1 (en) | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7262173B2 (en) | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
| US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| WO2000040592A1 (en) | 1998-12-30 | 2000-07-13 | Oligos Etc. Inc. | Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| US7098192B2 (en) * | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| AU7868400A (en) | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
| US20050186264A1 (en) | 2000-10-12 | 2005-08-25 | Kiani Mohammad F. | Targeting drug/gene carriers to irradiated tissue |
| US7060690B2 (en) | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| KR101265180B1 (ko) | 2002-01-17 | 2013-05-29 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물 |
| US20030147813A1 (en) | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US8969314B2 (en) * | 2003-07-31 | 2015-03-03 | Regulus Therapeutics, Inc. | Methods for use in modulating miR-122a |
| WO2005031002A2 (en) * | 2003-09-22 | 2005-04-07 | Rosetta Inpharmatics Llc | Synthetic lethal screen using rna interference |
| CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US20080171718A1 (en) | 2006-11-08 | 2008-07-17 | Brown Bob D | Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents |
| US8349812B2 (en) * | 2007-11-06 | 2013-01-08 | Adiutide Pharmaceuticals Gmbh | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties |
| JP5766608B2 (ja) | 2008-10-02 | 2015-08-19 | ヴェーイーベー ヴェーゼットウェーＶｉｂ Ｖｚｗ | フィラデルフィア染色体陽性白血病を治療するためのＰｌＧＦの阻害 |
| WO2012024396A2 (en) | 2010-08-17 | 2012-02-23 | Rutgers, The State University Of New Jersey | Compositions and methods for delivering nucleic acid molecules and treating cancer |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| WO2012122447A1 (en) | 2011-03-09 | 2012-09-13 | The Brigham And Women's Hospital, Inc. | Methods of using microrna-26a to promote angiogenesis |
| MY163004A (en) * | 2011-04-01 | 2017-07-31 | Ionis Pharmaceuticals Inc | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
| US10154962B2 (en) | 2013-06-03 | 2018-12-18 | Bar Ilan University | Liposomes for modulating Wiskott-Aldrich syndrome protein |
| MX389323B (es) | 2013-12-03 | 2025-03-20 | Univ Northwestern | Particulas liposomales, metodos para elaborarlas y sus usos. |
| US10206942B2 (en) | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| KR102755601B1 (ko) | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
| US10927379B2 (en) | 2016-09-16 | 2021-02-23 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| BR112019018555A2 (pt) | 2017-03-09 | 2020-04-14 | Univ Jefferson | métodos e composições para tratamento de cânceres utilizando antissenso |
| US12234457B2 (en) | 2017-04-19 | 2025-02-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for BCL2 inhibition |
| CN110650727A (zh) | 2017-04-19 | 2020-01-03 | 拜奥-帕斯控股股份有限公司 | 用于igf-1r抑制的p-乙氧基核酸 |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| JP2020517645A (ja) | 2017-04-19 | 2020-06-18 | バイオ−パス ホールディングス， インコーポレイテッド | Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸 |
| MX2021011760A (es) | 2019-03-28 | 2021-12-10 | Univ Jefferson | Metodos para el tratamiento de canceres usando antisentido. |
| CN112830354A (zh) | 2019-11-22 | 2021-05-25 | 富泰华工业（深圳）有限公司 | 基于区块链系统的电梯调度系统、装置、方法及存储介质 |
-
2018
- 2018-04-19 IL IL269608A patent/IL269608B2/en unknown
- 2018-04-19 KR KR1020197033988A patent/KR102775941B1/ko active Active
- 2018-04-19 CN CN201880033244.6A patent/CN110636836B/zh active Active
- 2018-04-19 JP JP2019556836A patent/JP7237009B2/ja active Active
- 2018-04-19 BR BR112019021771A patent/BR112019021771A2/pt active Search and Examination
- 2018-04-19 WO PCT/US2018/028259 patent/WO2018195249A1/en not_active Ceased
- 2018-04-19 EP EP18787720.4A patent/EP3612159A4/en active Pending
- 2018-04-19 CA CA3058018A patent/CA3058018A1/en active Pending
- 2018-04-19 US US16/606,419 patent/US11041153B2/en active Active
- 2018-04-19 AU AU2018255352A patent/AU2018255352B2/en active Active
- 2018-04-19 EA EA201992485A patent/EA201992485A1/ru unknown
- 2018-04-19 SG SG11201909336V patent/SG11201909336VA/en unknown
-
2019
- 2019-10-17 SA SA519410315A patent/SA519410315B1/ar unknown
-
2021
- 2021-06-04 US US17/339,366 patent/US12319911B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517632A5 (enExample) | ||
| IL269608B1 (en) | Compounds Containing Phosphorus-Ethoxy-Based Nucleic Acids for STAT3 Inhibition for Use in the Treatment of Cancer and Autoimmune Diseases | |
| JP2020517646A5 (enExample) | ||
| JP2020517645A5 (enExample) | ||
| CN108026533B (zh) | 拮抗性pdl1适体及其在癌症治疗中的应用 | |
| TWI459968B (zh) | 含有非電荷性親水性嵌段及側鏈之一部分導入疏水性基之陽離子性聚胺基酸嵌段所組成之共聚物及其使用 | |
| CN110643609B (zh) | 一种核苷类似物药物分子构建的药物适配体及其制备方法和应用 | |
| CN111315395A (zh) | 白细胞介素-18变体和使用方法 | |
| US12227745B2 (en) | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | |
| JP2020517631A5 (enExample) | ||
| US20120190732A1 (en) | Multifunctional Aptamer-Nucleic Acid Nanostructures for Tumor-Targeted Killing | |
| JP2020506189A5 (enExample) | ||
| JP2006502080A5 (enExample) | ||
| JP2014518612A5 (enExample) | ||
| US10532109B2 (en) | Peptide-DNA chimeras for treatment of HER overexpressing cancers | |
| US20210267897A1 (en) | Therapeutic Nanoparticles and Related Compositions, Methods and Systems | |
| Godbole et al. | Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer | |
| WO2024022332A1 (en) | Fap inhibitors | |
| CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| CN115820645B (zh) | 制备沉默nkg2a基因的nk细胞的方法及其用途 | |
| KR20200078303A (ko) | 신규한 dna 앱타머 및 이의 용도 | |
| CN103834035B (zh) | 一种阳离子化昆布多糖及其制备方法和应用 | |
| Ghosh et al. | Interferon therapy in lung cancer: current perspectives | |
| KR20110031168A (ko) | 약물 담체 | |
| KR20170063962A (ko) | 국소 투여용 리포플렉스의 신규 제조 방법 및 상기 리포플렉스를 사용하는 항 종양제 |